Press Releases

Dundalk, Ireland, March 1, 2024 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site has received three International Organization for Standardization (ISO) certifications: ISO 50001 – Energy Management Systems; ISO 14001 – Environmental Management Systems; and ISO 45001 – Occupational Health and Safety Management Systems. Meeting the criteria of these global standards demonstrates the company’s commitment to ESG (Environmental, Social and Governance) and its world-class performance in the areas of environmental stewardship, sustainable energy management, and the health and safety of employees.

The ISO 50001 and ISO 14001 certifications reflect the Ireland site’s outstanding efforts to decrease energy use and reduce emissions, with achievements in 2023 including a power supply made up of 100% renewable energy sources, a 1.7 GWh decrease in electricity usage, and a 3.4 GWh reduction in natural gas consumption. The site has also worked continually to mitigate its environmental impact through multiple waste reduction initiatives. Additionally, it has deployed comprehensive EHS (Environment, Health & Safety) programs in line with ISO 45001 to ensure a safe and healthy workplace.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, commented, “The ISO certifications mark a significant milestone for the Ireland site, and are a result of WuXi Biologics’ relentless focus and comprehensive measures regarding ESG management across all our sites. With the achievement of these certifications, we assure clients of our high standards in operations and services, prove our commitment to creating value for all stakeholders, and reinforce our pioneering role in sustainability for the greater good of society.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG

esg@wuxibiologics.com

Media

PR@wuxibiologics.com